SERDs (estrogen receptor degraders): all 235 studies that test it
Page 3 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.
- Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female SubjectsCompletedNCT02795039Phase 1
- Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT02760030Phase 2
- Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerCompletedNCT02650817Phase 1
- Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer PatientsStatus unknownNCT02646735Phase 2
- Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3
- Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC PatientsStatus unknownNCT02383030Phase 3
- A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerCompletedNCT02338349Phase 1
- Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABCWithdrawnNCT02140437Phase 2
- A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast CancerCompletedNCT02137083Phase 2
- The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast CancerStatus unknownNCT02072512Phase 2
- Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast CancerStatus unknownNCT02000193Phase 2
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryActive, not recruitingNCT01953588Phase 3
- Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRCompletedNCT01556191Phase 2
- Molecular Imaging of Fulvestrant Effects on Availability of ER Binding SitesCompletedNCT01377324Phase 2
- Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenStatus unknownNCT01266213Phase 2
- Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)CompletedNCT00944918Phase 3
- A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)Status unknownNCT00927511Phase 2
- Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast CancerSuspendedNCT00738777Phase 2
- Second Line Breast Cancer TrialCompletedNCT00635713Phase 3
- Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast CancerCompletedNCT00629616Phase 2
- Efficacy and Safety of 500mg of FulvestrantActive, not recruitingNCT00585507Phase 2
- Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular StudiesCompletedNCT00417430Phase 2
- Faslodex 500mg Multiple Dose Tolerability Study in BC PatientsCompletedNCT00328120Phase 1
- Faslodex Advanced Breast Cancer Local Chinese StudyCompletedNCT00327769Phase 3
- SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast CancerCompletedNCT00272740Phase 2
- Fulvestrant in Treating Patients With Advanced Prostate CancerCompletedNCT00244998Phase 2
- A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast CancerCompletedNCT00241449Phase 3
- A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast CancerCompletedNCT00234403Phase 2
- Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast CancerCompletedNCT00146601Phase 2
- Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the BreastStatus unknownNCT00126464Not applicable
- Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00100854Phase 2
- Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast CancerCompletedNCT00093002Phase 2
- The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast CancerCompletedNCT00065325Phase 3
- ICI 182780 in Treating Women With Metastatic Breast CancerCompletedNCT00012025Phase 2
- ICI 182780 in Treating Women With Stage I or Stage II Primary Breast CancerTerminatedNCT00010153Phase 3